What Happened?
Hayward, CA-based Advanced Cell Diagnostics Appointed Yuling Luo as Chief Executive Officer
About the Company
Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry. ACD’s products and services are based on its proprietary RNAscope® Technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. In addition to its ongoing efforts to develop proprietary diagnostic tests for cancer management, ACD also establishes partnerships with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development. These internal and external efforts will continue to position ACD as a leader in molecular diagnostics and companion diagnostics. The company’s technology overcomes critical hurdles in the identification and validation of biomarkers for companion diagnostics. ACD’s RNAscope® platform provides a new way of localizing and measuring RNA in situ with exceptional levels of sensitivity, specificity, and the ability to multiplex. Turnaround time for a new assay is reduced to three weeks. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity, thus shortening the path to personalized medicine.
About the Person
Dr. Luo is an entrepreneur with more than 14 years of start-up experience in leadership and innovation. Before ACD, Dr. Luo was a founder of Panomics (previously named Genospectra before its acquisition of Panomics), a life science company that was acquired by Affymetrix in 2008. At Panomics, Dr. Luo served various roles including Vice President, Functional Genomics and Chief Scientific Officer and he led the development and launch of all of its flagship product lines. Prior to Panomics, Dr. Luo was one of the earliest senior scientists at Exelixis, where he led a team to identify and validate novel therapeutic targets. Dr. Luo has published many research papers in top peer-reviewed journals. His inventions are the subject of over a dozen patents and patent pending applications. Dr. Luo received his doctorate in biochemistry from Case Western Reserve University and conducted post-doctoral research at the University of Pennsylvania.
Info Source
Press Release
Short Profile